Evidence map›Paper›PMID 37952909›Full record

Trial reportJournal of affective disorders2024

Impact of sleep disruption on BDD symptoms and treatment response.

Emily E Bernstein, Dalton Klare, Hilary Weingarden, Jennifer L Greenberg, Ivar Snorrason, Susanne S Hoeppner, Rachel Vanderkruik, Oliver Harrison, Sabine Wilhelm

Abstract readRandomized Controlled Trial
In one paragraph

Trial report in Journal of affective disorders, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Clinical utility of digital technologies in Parkinson's disease.Journal of neural transmission (Vienna, Austria : 1996) · 2026
    Review
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Emily E BernsteinMassachusetts General Hospital, United States of America; Harvard Medical School, United States of America. Electronic address: eebernstein@mgh.harvard.edu.
Dalton KlareMassachusetts General Hospital, United States of America.
Hilary WeingardenMassachusetts General Hospital, United States of America; Harvard Medical School, United States of America.
Jennifer L GreenbergMassachusetts General Hospital, United States of America; Harvard Medical School, United States of America.
Ivar SnorrasonMassachusetts General Hospital, United States of America; Harvard Medical School, United States of America.
Susanne S HoeppnerMassachusetts General Hospital, United States of America; Harvard Medical School, United States of America.
Rachel VanderkruikMassachusetts General Hospital, United States of America; Harvard Medical School, United States of America.
Oliver HarrisonKoa Health, United Kingdom.
Sabine WilhelmMassachusetts General Hospital, United States of America; Harvard Medical School, United States of America.

Funding

Smartphone-based digital phenotyping to detect high-risk affect states in body dysmorphic disorderK23MH119372 · NIMH · MASSACHUSETTS GENERAL HOSPITAL · PI WEINGARDEN, HILARY · 2019 to 2024
$922k
NIMH NIH HHS K23 MH119372Wellcome Trust
6 · The paper itself

Abstract

backgroundBody dysmorphic disorder (BDD) is severe, undertreated, and relatively common. Although gold-standard cognitive behavioral therapy (CBT) for BDD has strong empirical support, a significant number of patients do not respond. More work is needed to understand BDD's etiology and modifiable barriers to treatment response. Given its high prevalence and impact on the development, maintenance, and treatment of related, frequently comorbid disorders, sleep disruption is a compelling, but not-yet studied factor.

methodsData were drawn from a randomized controlled trial of guided smartphone app-based CBT for BDD. Included participants were offered 12-weeks of treatment, immediately (n = 40) or after a 12-week waitlist (n = 37). Sleep disruption and BDD symptom severity were assessed at baseline, week-6, and week-12.

resultsHypotheses and analysis plan were pre-registered. Two-thirds of patients reported significant insomnia symptoms at baseline. Baseline severity of sleep disruption and BDD symptoms were not related (r = 0.02). Pre-treatment sleep disruption did not predict BDD symptom reduction across treatment, nor did early sleep improvements predict greater BDD symptom improvement. Early BDD symptom improvement also did not predict later improvements in sleep. LIMITATIONS: Limitations include the small sample, restricted ranges of BDD symptom severity and treatment response, and few metrics of sleep disruption.

conclusionsAlthough insomnia was disproportionately high in this sample and both BDD symptoms and sleep improved in treatment, results suggest sleep and BDD symptoms may function largely independent of one another. More work is encouraged to replicate and better understand findings as well as potential challenges and benefits of addressing sleep in BDD.

Indexed as

Body Dysmorphic DisordersCognitive Behavioral TherapySleep Initiation and Maintenance DisordersHumansSleepTreatment OutcomeBody dysmorphic disorderCognitive behavioral therapyInsomniaSleepSmartphone

Identifiers

PMID37952909
PMCPMC10842714

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.